References
- Graf P. Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity. Rhinology 1996; 34: 9–13
- Svensson C, Pipkorn U, Alkner U, Baumgarten C R, Persson C GA. Topical vasoconstrictor (oxymetazoline) does not affect histamine-induced mucosal exudation of plasma in human nasal airways. Clin Exp Allergy 1992; 22: 411–6
- Raphael G D, Jeney E V, Baraniuk J N, Kim I, Meredith S D, Kaliner M A. Pathophysiology of rhinitis. Lacto-ferrin and lysozvme in nasal secretions. J Clin Invest 1989; 84: 1528–35
- Housley D G, Eccles R, Richards R J. Gender difference in the concentration of the antioxidant uric acid in human nasal lavage. Acta Otolaryngol (Stockh) 1996; 116: 751–4
- Smolelis A N, Harstei S E. The determination of lysozyme. J Bacteriol 1949; 58: 731–9
- Bradford M M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–54
- Raphael G D, Meredith S D, Baraniuk J N, Druce H M, Banks S M, Kaliner M A. The pathophysiology of rhinitis II. Assessment of the sources of protein in histamine-induced secretions. Am Rev Respir Dis 1989; 139: 791–800
- Bende M, Hansell P, Intaglietta M, Arfors K E. Effect of oxymetazoline nose drops on vascular-permeability of the nasal-mucosa in the rabbit after provocation with leukotriene-b4. J Oto Rhino Laryngol 1992; 54: 270–4
- Bende M, Loth S. Vascular effects of topical oxymetazoline on human nasal mucosa. J Laryngol Otol 1986; 100: 285–8
- Andersson K E, Bende M. Adrenoceptors in the control of human nasal mucosal blood flow. Ann Otol Rhinol Laryngol 1984; 93: 179–82